Cells 2012, 1(2), 153-167; doi:10.3390/cells1020153
Article

Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis?

1 Department of Clinical and Experimental Medicine, Infectious Medicine Faculty of Health Sciences, Linköping University, 581 83 Linköping, Sweden 2 The Åland Borrelia Group, Åland, 22100 Mariehamn, Åland, Finland 3 Department of Infectious Diseases, County Council of Östergötland, 581 85 Linköping, Sweden 4 Center for Clinical Research (CKF) Dalarna, 791 36 Falun, Sweden 5 Department of Clinical and Experimental Medicine, Clinical Immunology, Linköping University, S-581 83 Linköping, Sweden 6 Department of Clinical Immunology and Transfusion Medicine, County Council of Östergötland, 581 85 Linköping, Sweden 7 Department of Laboratory Medicine, NÄL, 461 85 Trollhättan, Sweden
* Author to whom correspondence should be addressed.
Received: 1 April 2012; in revised form: 7 May 2012 / Accepted: 8 May 2012 / Published: 8 June 2012
(This article belongs to the Special Issue ELISPOT Research)
PDF Full-text Download PDF Full-Text [123 KB, uploaded 8 June 2012 13:48 CEST]
Abstract: The aim of this prospective study was to investigate the diagnostic performance of Borrelia (Bb)-induced interferon (IFN)-γ secretion detected by ELISPOT modified to be feasible for clinical laboratories as a supplementary test to the laboratory diagnosis of Lyme neuroborreliosis (LNB) in an endemic setting. Between 2002 and 2004, patients with symptoms of suspected clinical LNB were included in a study conducted on the Åland islands in the Finnish archipelago, which is a hyper-endemic area for Lyme borreliosis (LB). Fourteen patients with confirmed LNB and 103 patients with non-LNB were included, and the numbers of spontaneous and Bb-induced IFN-γ-secreting cells were assayed by the ELISPOT test. The ELISPOT assay showed a weak diagnostic performance with a sensitivity of 36% and a specificity of 82%. The findings in this study show that this ELISPOT-assay modified to be feasible in clinical routine laboratories is not useful as a supplementary diagnostic tool in the laboratory diagnosis of patients with clinically suspected LNB.
Keywords: Borrelia burgdorferi; neuroborreliosis; ELISPOT; cerebrospinal fluid; diagnostic test; sensitivity; specificity

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Nordberg, M.; Forsberg, P.; Nyman, D.; Skogman, B.H.; Nyberg, C.; Ernerudh, J.; Eliasson, I.; Ekerfelt, C. Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? Cells 2012, 1, 153-167.

AMA Style

Nordberg M, Forsberg P, Nyman D, Skogman BH, Nyberg C, Ernerudh J, Eliasson I, Ekerfelt C. Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? Cells. 2012; 1(2):153-167.

Chicago/Turabian Style

Nordberg, Marika; Forsberg, Pia; Nyman, Dag; Skogman, Barbro H.; Nyberg, Clara; Ernerudh, Jan; Eliasson, Ingvar; Ekerfelt, Christina. 2012. "Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis?" Cells 1, no. 2: 153-167.

Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert